Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 565

1.

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.

Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, Dew MA, Butters MA, Stack JA, Begley AE, Reynolds CF 3rd.

Lancet. 2015 Dec 12;386(10011):2404-12. doi: 10.1016/S0140-6736(15)00308-6. Epub 2015 Sep 27. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.

PMID:
26423182
2.

The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study.

Fisher LB, Fava M, Doros GD, Alpert JE, Henry M, Huz I, Freeman MP.

J Nerv Ment Dis. 2015 Oct;203(10):762-8. doi: 10.1097/NMD.0000000000000364.

PMID:
26348584
3.

Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.

Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H.

J Clin Psychiatry. 2015 Sep;76(9):1232-40. doi: 10.4088/JCP.14m09689.

4.

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H.

J Clin Psychiatry. 2015 Sep;76(9):1224-31. doi: 10.4088/JCP.14m09688.

5.

Adjunctive Antipsychotic Prescriptions for Outpatients with Depressive Disorders in Asia: The Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) Study.

Park SC, Shinfuku N, Maramis MM, Lee MS, Park YC.

Am J Psychiatry. 2015 Jul;172(7):684-5. doi: 10.1176/appi.ajp.2015.14121590. No abstract available.

PMID:
26130203
6.

MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder.

Gabriela Nielsen M, Congiu C, Bortolomasi M, Bonvicini C, Bignotti S, Abate M, Milanesi E, Conca A, Cattane N, Tessari E, Gennarelli M, Minelli A.

J Affect Disord. 2015 Sep 1;183:179-86. doi: 10.1016/j.jad.2015.05.003. Epub 2015 May 11.

PMID:
26021967
7.

Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.

Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P.

J Clin Psychiatry. 2015 Apr;76(4):e487-98. doi: 10.4088/JCP.14r09204.

PMID:
25919841
8.

Less is more--possible option in the treatment of depression.

Dadić-Hero E, Knez R, Rebić J.

Coll Antropol. 2014 Dec;38(4):1207-9.

PMID:
25842759
9.

Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group.

Sühs KW, Correll C, Eberlein CK, Pul R, Frieling H, Bleich S, Kahl KG.

Brain Behav. 2015 Apr;5(4):e00318. doi: 10.1002/brb3.318. Epub 2015 Feb 19.

10.

The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression.

Kautzky A, Baldinger P, Souery D, Montgomery S, Mendlewicz J, Zohar J, Serretti A, Lanzenberger R, Kasper S.

Eur Neuropsychopharmacol. 2015 Apr;25(4):441-53. doi: 10.1016/j.euroneuro.2015.01.001. Epub 2015 Feb 2.

PMID:
25769916
11.

The Impact of Accelerated HF-rTMS on the Subgenual Anterior Cingulate Cortex in Refractory Unipolar Major Depression: Insights From 18FDG PET Brain Imaging.

Baeken C, Marinazzo D, Everaert H, Wu GR, Van Hove C, Audenaert K, Goethals I, De Vos F, Peremans K, De Raedt R.

Brain Stimul. 2015 Jul-Aug;8(4):808-15. doi: 10.1016/j.brs.2015.01.415. Epub 2015 Feb 7.

PMID:
25744500
12.

Prefrontal glucose metabolism in medication-resistant major depression.

Li CT, Su TP, Wang SJ, Tu PC, Hsieh JC.

Br J Psychiatry. 2015 Apr;206(4):316-23. doi: 10.1192/bjp.bp.113.140434. Epub 2015 Feb 5.

PMID:
25657357
13.

Reversal of non-suppression of cortisol levels in a patient with refractory depression receiving ketamine.

Ostroff R, Kothari JS.

Am J Psychiatry. 2015 Jan;172(1):95-6. doi: 10.1176/appi.ajp.2014.14060776. No abstract available.

PMID:
25553498
14.

Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.

Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu039. doi: 10.1093/ijnp/pyu039.

15.

The role of the potassium channel gene KCNK2 in major depressive disorder.

Congiu C, Minelli A, Bonvicini C, Bortolomasi M, Sartori R, Maj C, Scassellati C, Maina G, Trabucchi L, Segala M, Gennarelli M.

Psychiatry Res. 2015 Feb 28;225(3):489-92. doi: 10.1016/j.psychres.2014.11.061. Epub 2014 Dec 9.

PMID:
25535009
16.

Moderators of response to cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care.

Button KS, Turner N, Campbell J, Kessler D, Kuyken W, Lewis G, Peters TJ, Thomas L, Wiles N.

J Affect Disord. 2015 Mar 15;174:272-80. doi: 10.1016/j.jad.2014.11.057. Epub 2014 Dec 6.

PMID:
25527998
17.

Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial.

McGirr A, Van den Eynde F, Tovar-Perdomo S, Fleck MP, Berlim MT.

J Affect Disord. 2015 Mar 1;173:216-20. doi: 10.1016/j.jad.2014.10.068. Epub 2014 Nov 11.

PMID:
25462419
18.

Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopram.

Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandel P, Haffen E.

Clin Neurophysiol. 2015 Jun;126(6):1185-9. doi: 10.1016/j.clinph.2014.09.026. Epub 2014 Oct 5.

PMID:
25454337
19.

Personality traits as predictors for the outcome of lithium augmentation in treatment-resistant depression.

Takahashi M, Suzuki M, Muneoka K, Tsuruoka Y, Sato K, Shirayama Y.

Psychiatry Res. 2014 Dec 30;220(3):1144-6.

PMID:
25453642
20.

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90. doi: 10.1038/npp.2014.298.

PMID:
25374095
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk